EQL Pharma Balance Sheet Health
Financial Health criteria checks 3/6
EQL Pharma has a total shareholder equity of SEK173.0M and total debt of SEK98.0M, which brings its debt-to-equity ratio to 56.7%. Its total assets and total liabilities are SEK339.6M and SEK166.6M respectively. EQL Pharma's EBIT is SEK30.3M making its interest coverage ratio 7.3. It has cash and short-term investments of SEK10.4M.
Key information
56.7%
Debt to equity ratio
kr98.02m
Debt
Interest coverage ratio | 7.3x |
Cash | kr10.41m |
Equity | kr173.03m |
Total liabilities | kr166.59m |
Total assets | kr339.62m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7JK's short term assets (SEK170.5M) exceed its short term liabilities (SEK133.5M).
Long Term Liabilities: 7JK's short term assets (SEK170.5M) exceed its long term liabilities (SEK33.1M).
Debt to Equity History and Analysis
Debt Level: 7JK's net debt to equity ratio (50.6%) is considered high.
Reducing Debt: 7JK's debt to equity ratio has increased from 0% to 56.7% over the past 5 years.
Debt Coverage: 7JK's debt is not well covered by operating cash flow (19.2%).
Interest Coverage: 7JK's interest payments on its debt are well covered by EBIT (7.3x coverage).